Genetic Determinants of Acenocoumarol and Phenprocoumon Maintenance Dose Requirements

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2009 Dec 19

PMID 20020283

Citations 14

Authors

Janne Cadamuro

Benjamin Dieplinger

Thomas Felder

Igor Kedenko

Thomas Mueller

Meinhard Haltmayer

Wolfgang Patsch

Hannes Oberkofler

Affiliations

Soon will be listed here.

Abstract

Objective: The variability in warfarin dose requirement is attributable to genetic and environmental factors. Acenocoumarol (AC) and phenprocoumon (PC) are coumarin derivates widely prescribed in European countries for the prevention and treatment of thromboembolic events. The aim of our study was to investigate the contribution of genes involved in the vitamin K cycle to AC and PC maintenance doses.

Methods: Common single nucleotide polymorphisms (SNPs) in the genes encoding cytochrome P450 family member 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), gamma-glutamyl carboxylase (GGCX), calumenin (CALU) and apolipoprotein E (APOE) were studied in 206 patients receiving AC or PC.

Results: Compared to patients with the VKORC1 C1173C genotype, maintenance doses for AC or PC were reduced to 74.6 or 70.2% in heterozygous C1173T subjects and to 48.6 or 48.1% in homozygous T1173T subjects (P < 0.0001). Furthermore maintenance doses for AC and PC were significantly lower in heterozygous CYP2C9*1*3, CYP2C9*2*3, and in CYP2C9*3*3 homozygote individuals compared to homozygous CYP2C9*1*1 subjects (P = 0.0004 and P = 0.0017, respectively). A multiple regression model including age, sex, last INR, VKORC1, and CYP2C9 genotypes explained ~50% of the variability in AC/PC dose requirements. CALU genotype combinations showed minor effects on PC dose requirements. No associations with AC or PC dose requirements were observed for sequence substitutions in the GGCX or APOE genes.

Conclusion: These results reveal that interindividual variability in weekly AC and PC maintenance dose requirement is mainly dependent on the VKORC1 1173C>T and the CYP2C9*3 alleles. VKORC1 and CYP2C9 genotyping might provide helpful information to prevent serious bleeding events in subjects receiving AC or PC.

Citing Articles

A clinical conundrum: review of anticoagulation in pregnant women with mechanical prosthetic heart valves.

Jenneker M, Ramnarain H, Sebitloane H Cardiovasc J Afr. 2022; 33(6):322-328.

PMID: 36162856 PMC: 10031849. DOI: 10.5830/CVJA-2022-028.

Pharmacogenetic landscape of Metabolic Syndrome components drug response in Tunisia and comparison with worldwide populations.

Jmel H, Romdhane L, Ben Halima Y, Hechmi M, Naouali C, Dallali H PLoS One. 2018; 13(4):e0194842.

PMID: 29652911 PMC: 5898725. DOI: 10.1371/journal.pone.0194842.

Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.

Ajmi M, Omezzine A, Achour S, Amor D, Hamdouni H, Ismail F Eur J Clin Pharmacol. 2018; 74(6):711-722.

PMID: 29479633 DOI: 10.1007/s00228-018-2423-7.

Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China.

Wang L, Aikemu A, Yibulayin A, Du S, Geng T, Wang B BMC Genet. 2015; 16:66.

PMID: 26091847 PMC: 4475291. DOI: 10.1186/s12863-015-0232-x.

Pharmacogenetics aspects of oral anticoagulants therapy.

Militaru F, Vesa S, Pop T, Buzoianu A J Med Life. 2015; 8(2):171-5.

PMID: 25866574 PMC: 4392103.

References

Reitsma P, van der Heijden J, Groot A, Rosendaal F, Buller H . A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med. 2005; 2(10):e312. PMC: 1251635. DOI: 10.1371/journal.pmed.0020312. View

Hummers-Pradier E, Hess S, Adham I, Papke T, Pieske B, Kochen M . Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur J Clin Pharmacol. 2003; 59(3):213-9. DOI: 10.1007/s00228-003-0580-8. View

Cooper G, Johnson J, Langaee T, Feng H, Stanaway I, Schwarz U . A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood. 2008; 112(4):1022-7. PMC: 2515139. DOI: 10.1182/blood-2008-01-134247. View

Lindh J, Holm L, Andersson M, Rane A . Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis. Eur J Clin Pharmacol. 2008; 65(4):365-75. DOI: 10.1007/s00228-008-0584-5. View

Gonzalez-Conejero R, Corral J, Roldan V, Ferrer F, Sanchez-Serrano I, Sanchez-Blanco J . The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. J Thromb Haemost. 2007; 5(8):1701-6. DOI: 10.1111/j.1538-7836.2007.02630.x. View

He M, Korzekwa K, Jones J, Rettie A, TRAGER W . Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys. 1999; 372(1):16-28. DOI: 10.1006/abbi.1999.1468. View

Taube J, Halsall D, Baglin T . Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 2000; 96(5):1816-9. View

Schalekamp T, Brasse B, Roijers J, van Meegen E, van der Meer F, van Wijk E . VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther. 2006; 81(2):185-93. DOI: 10.1038/sj.clpt.6100036. View

Vecsler M, Loebstein R, Almog S, Kurnik D, Goldman B, Halkin H . Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost. 2006; 95(2):205-11. DOI: 10.1160/TH05-06-0446. View

10.

Caldwell M, Awad T, Johnson J, Gage B, Falkowski M, Gardina P . CYP4F2 genetic variant alters required warfarin dose. Blood. 2008; 111(8):4106-12. PMC: 2288721. DOI: 10.1182/blood-2007-11-122010. View

11.

Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden A, van Schaik R, Hofman A . A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet. 2009; 18(19):3758-68. DOI: 10.1093/hmg/ddp309. View

12.

Hirsh J, Dalen J, Anderson D, Poller L, Bussey H, Ansell J . Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001; 119(1 Suppl):8S-21S. DOI: 10.1378/chest.119.1_suppl.8s. View

13.

Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K . Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res. 2006; 120(2):181-6. DOI: 10.1016/j.thromres.2006.09.007. View

14.

Saupe J, Shearer M, Kohlmeier M . Phylloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. Am J Clin Nutr. 1993; 58(2):204-8. DOI: 10.1093/ajcn/58.2.204. View

15.

Wajih N, Sane D, Hutson S, Wallin R . The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats. J Biol Chem. 2004; 279(24):25276-83. DOI: 10.1074/jbc.M401645200. View

16.

Kirchheiner J, Ufer M, Walter E, Kammerer B, Kahlich R, Meisel C . Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics. 2004; 14(1):19-26. DOI: 10.1097/00008571-200401000-00002. View

17.

Oberkofler H, Linnemayr V, Weitgasser R, Klein K, Xie M, Iglseder B . Complex haplotypes of the PGC-1alpha gene are associated with carbohydrate metabolism and type 2 diabetes. Diabetes. 2004; 53(5):1385-93. DOI: 10.2337/diabetes.53.5.1385. View

18.

Wadelius M, Chen L, Eriksson N, Bumpstead S, Ghori J, Wadelius C . Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2006; 121(1):23-34. PMC: 1797064. DOI: 10.1007/s00439-006-0260-8. View

19.

Wang D, Chen H, Momary K, Cavallari L, Johnson J, Sadee W . Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood. 2008; 112(4):1013-21. PMC: 2515137. DOI: 10.1182/blood-2008-03-144899. View

20.

Schalekamp T, Oosterhof M, van Meegen E, van der Meer F, Conemans J, Hermans M . Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther. 2004; 76(5):409-17. DOI: 10.1016/j.clpt.2004.08.006. View